Prelude Therapeutics Inc
(NAS:PRLD)
$
3.62
-0.11 (-2.95%)
Market Cap: 198.84 Mil
Enterprise Value: 14.56 Mil
PE Ratio: 0
PB Ratio: 0.94
GF Score: 38/100 Prelude Therapeutics Inc (PRLD) Transcripts
- Prelude Therapeutics Inc at Morgan Stanley Global Healthcare Conference TranscriptSep 12, 2023
- Prelude Therapeutics Inc at Jefferies Healthcare Conference TranscriptJun 07, 2023
- Prelude Therapeutics Inc at JMP Securities Life Sciences Conference TranscriptMay 15, 2023
- Prelude Therapeutics Inc at Bank of America Global Healthcare Conference TranscriptMay 10, 2023
- Prelude Therapeutics Inc at H.C. Wainwright BioConnect Investor Conference TranscriptMay 02, 2023
- Prelude Therapeutics Inc at Morgan Stanley Global Healthcare Conference TranscriptSep 14, 2022
- Prelude Therapeutics Inc at Barclays Global Healthcare Conference TranscriptMar 17, 2022
- Prelude Therapeutics Inc at Evercore ISI HealthCONx Virtual Conference TranscriptDec 01, 2021
- Prelude Therapeutics Inc at H C Wainwright Precision Oncology Conference (Virtual) TranscriptOct 20, 2021
- Prelude Therapeutics Inc at Morgan Stanley Global Healthcare Conference (Virtual) TranscriptSep 09, 2021
- Prelude Therapeutics Inc at Goldman Sachs Global Healthcare Conference (Virtual) TranscriptJun 09, 2021
- Prelude Therapeutics Inc at Bank of America Global Research Healthcare Conference (Virtual) TranscriptMay 12, 2021
- Prelude Therapeutics Inc at Barclays Global Healthcare Conference (Virtual) TranscriptMar 10, 2021
- 1